United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dell Technologies

L3Harris

The stock market enjoyed a strong year in 2024 as the S&P 500 hit new records. The challenge for investors looking to get into the market amid such a strong bull run, however, is that valuations for some stocks have gotten high, perhaps even wildly overpriced.

Got $5,000? These 3 Stocks Are Absurdly Cheap Buys Heading Into 2025

Cameco

SPDR S&P Regional Banking ETF

Volume is what drives the entire market, and that is a fact that often gets lost in the sea of indicators, patterns, and trend lines that dominate today's concept of analysis. However, most investors fail to realize that these indicators and patterns are nothing more than price action recognition, and what drives price action is volume.

Top 3 Stocks Seeing a Spike in Call Option Volume

Collaboration will leverage Atavistik Bio's proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik Bio has rapidly identified novel, functional, allosteric binding pockets across a broad range of intractable target classes Collaboration with Pfizer will enable Atavistik Bio to extend the reach of its platform to potentially address a broader range of oncology indications, while simultaneously progressing its internal pipeline of precision oncology small molecule therapies CAMBRIDGE, Mass., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology company committed to discovering the next generation of precision allosteric therapeutics inspired by the body's natural regulators, today announced that it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant unmet medical needs.

Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics

Alibaba

Ford Motor Company

Intel

AT&T

Warren Buffett, one of the most famous investors of all time, made his billions with a getting rich slowly strategy and cleverly finding resilient and promising but undervalued businesses.

ChatGPT picks 5 undervalued stocks to watch at the start of 2025

Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 billion through balance sheet optimization. Investing $10.7-$11.7 billion in R&D, focusing on obesity treatments, oncology, and vaccines to address unmet needs.

Pfizer's 2025 Comeback: What's Driving Growth

Sangamo Therapeutics

The small-cap won't receive an expected payout in the first quarter, creating a cash overhang.

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc PFE.

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents protecting their proprietary drugs expire.

3 Reasons to Buy Pfizer Stock Like There's No Tomorrow

Pharmaceutical giant Pfizer Inc. NYSE: PFE stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down.

Pfizer: 4 Reasons to Buy This Stock

Bristol-Myers

Sanofi

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's Sanofi at the start of 2025, according to data analyzed by healthcare research firm 3 Axis Advisors.

Drugmakers to raise US prices on over 250 medicines starting Jan. 1

Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its target in a late-stage trial, with Pfizer previously expected to seek regulatory approval in 2025. “We were extremely surprised and very disappointed,” said Sangamo's CEO, Sandy Macrae.

Sangamo Therapeutics down 50% premarket on Pfizer blow

Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.

Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

As President-elect Donald Trump prepares for his inauguration, his administration is gearing up to roll out significant policy shifts.

25 Worst Stocks to Own in January

Kirk Spano thinks Pfizer is poised to be a major AI winner, especially in cancer treatment. Potentially making it easier to manage like AIDS.

Pfizer: One Of The Next Big AI Winners

Abbott Labs

British American Tobacco

Chevron

EOG Resources

Hess

Hershey

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Procter & Gamble

Permian Resources Corp

Reckitt Benckiser Group PLC

Molson Coors Brewing

Unilever

Exxon Mobil

I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is not a get-rich-quick strategy, it requires commitment and a long-term mindset. Making a New Year's resolution is a great way to help maintain that mindset. I discuss two scenarios of hypothetical investors who start their journey in 2025. I detail the significant impact a long-term commitment – even without additional investments – can make.

My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks

Johnson & Johnson

Pubmatic

Sirius XM Holdings Inc

Investors have plenty to be thankful for in 2024. They've witnessed the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all rocket higher by a double-digit percentage and head to multiple record-closing highs.

5 Unbeatable Stocks I'm Eager to Buy in 2025

Ares Capital

Enbridge

Enterprise Products Partners

Honda

I like every part of the phrase "ultra-high-yield dividend stocks." Investing in stocks allows me to own portions of great businesses.

My 5 Favorite Ultra-High-Yield Dividend Stocks to Buy for 2025

Realty Income Corp

It's been an interesting year for the stock market. The broader benchmark S&P 500 (^GSPC -1.11%) blazed roughly 24.5% higher (as of Dec. 27), thanks largely to eight high-flying tech stocks with market caps exceeding $1 trillion.

360 Stocks in the S&P 500 Underperformed the Benchmark's 2024 Gain of 24%. Here's 2 High-Yielding S&P 500 Stocks to Buy in 2025, According to Wall Street.

Pfizer (PFE 0.23%) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market. The company generated billions of dollars in revenue thanks to its coronavirus vaccine and treatment, even reaching a record of more than $100 billion in total company revenue in 2022.

Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.

LyondellBasell Industries

Altria

Verizon

Investors love dividend stocks, especially the blue-chip variety because they offer a significant income stream and have massive total return potential.

Start Off the New Year With 5 Blue Chip Dividend Stocks That Pay 6% and Higher Yields

News for Pfizer Stock (PFE)